INS-IGF2

Across TCGA pan-cancer cohorts, INS-IGF2 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of INS-IGF2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where INS-IGF2 RNA is repressed in tumor relative to normal tissue. In most cancer types INS-IGF2 is over-expressed in tumor, although a few such as LIHC and THCA show the opposite, repressed pattern.

LIHC, THCA, and CHOL are the cancer types where INS-IGF2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in INS-IGF2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	−2.517	<.001	9	view →
THCA	All	All	−0.009	<.001	6	view →
CHOL	Female	All	−3.146	<.001	5	view →
KIRC	Female	All	−0.012	.011	3	view →
HNSC	All	All	−0.005	.017	2	view →
KIRP	All	All	−0.009	.042	1	view →
KICH	All	All	−0.008	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

INS-IGF2–LIHC

Open the LIHC breakdown →